| ASA |
|---|
| 75-162 mg/d indefinitely (Class I, Level A) |
| Clopidogrel |
| 75 mg/d indefinitely in ASA allergy or intolerance (Class IIa, Level C) |
| ASA + clopidogrel |
| Post-BMS |
| ASA 75-162 mg/d and clopidogrel 75 mg/d for ≥ 1 mo (Class I, Level B) |
| ASA 75-162 mg/d and clopidogrel 75 mg/d for up to 12 mo in the absence of an excessive risk of bleeding (Class I, Level B) |
| For patients with a high risk of bleeding, a BMS should be implanted and ASA 75-162 mg/d and clopidogrel 75 mg/d continued for a minimum of 2 wk (Class I, Level B) |
| ASA 75-162 mg/d and clopidogrel 75 mg/d beyond 1 y may be considered if the risk of stent thrombosis is high and the risk of bleeding is low (Class IIb, Level C) |
| Post-DES |
| ASA 75-162 mg/d and clopidogrel 75 mg/d for 12 mo (Class I, Level A) |
| ASA 75-162 mg/d and clopidogrel 75 mg/d beyond 1 y may be considered if the risk of stent thrombosis is high and the risk of bleeding is low (Class IIb, Level C) |
| ASA + prasugrel |
| Post-ACS |
| ASA 75-162 mg/d and prasugrel 10 mg/d may be considered in patients with increased risk of stent thrombosis (eg, STEMI, history of diabetes mellitus, or prior documented stent thrombosis) (Class IIa, Level B) |
| ASA 75-162 mg/d plus prasugrel 10 mg/d should be avoided in patients with an increased bleeding risk, likely to undergo CABG within 7 d, with a history of stroke or TIA, aged ≥ 75 y, or weight < 60 kg (Class III, Level B) |
| ASA + ticagrelor |
| Post-ACS |
| ASA 75-162 mg/d and ticagrelor 90 mg twice daily for 12 mo (Class I, Level B) |
The clinical reason for PCI must be taken into consideration. Specifically, if there is a discrepancy in the suggested duration of therapy, the longer duration of dual antiplatelet therapy is preferred.
ACS, acute coronary syndrome; ASA, acetylsalicylic acid; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack.